Example: Heart Attack

Search clinical trials for: FOLFIRI

Total 177 results

NCT05004350

Recruiting

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Conditions: BRAF V600E, Metastatic Colorectal Cancer
NCT04185883

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
NCT05362617

Recruiting

mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy

Conditions: Metastatic Colorectal Cancer
NCT05332002

Not yet recruiting

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Conditions: Gastro-Intestinal Cancer
NCT04952753

Recruiting

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Conditions: Metastatic Colorectal Cancer
NCT05087992

Recruiting

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Conditions: Gastrointestinal Cancer, Metastatic
NCT03081143

Recruiting

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Conditions: Advanced Gastric or EGJ Cancer
NCT04793958

Recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer
NCT05352165

Not yet recruiting

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer

Conditions: Neoadjuvant Therapy
NCT03250832

Active, not recruiting

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Conditions: Neoplasms
NCT05312398

Recruiting

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Conditions: Metastatic Colorectal Adenocarcinoma
NCT04256707

Recruiting

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Conditions: Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
NCT01946074

Active, not recruiting

A Study of ABT-165 in Subjects With Solid Tumors

Conditions: Advanced Solid Tumors
NCT02439385

Completed

Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis

Conditions: Colorectal Cancer
NCT02162563

Recruiting

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

Conditions: Colorectal Cancer, Liver Metastases
NCT03082209

Completed

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Conditions: Advanced Solid Tumors, Cancer, Hematologic Malignancies
NCT02404935

Completed

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

Conditions: Metastatic Colorectal Cancer
NCT02563002

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Conditions: Colorectal Carcinoma
NCT04553692

Recruiting

Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers

Conditions: Solid Tumor, Colorectal Cancer, Gastric Cancer, Non Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
NCT05084859

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Conditions: Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
NCT03635021

Recruiting

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Conditions: Colorectal Cancer
NCT03454620

Completed

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Conditions: Metastatic Colorectal Cancer, Solid Tumor
NCT04247256

Recruiting

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Conditions: Metastatic Colorectal Cancer
NCT02820857

Recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Conditions: Neuroendocrine Carcinomas
NCT03829410

Recruiting

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Conditions: Metastatic Colorectal Cancer, KRAS Gene Mutation

Search clinical trials for: FOLFIRI

Medical Conditions

Sponsors and Collaborators

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations